Meckler Files SC 13D for Indaptus Therapeutics
Ticker: INDP · Form: SC 13D · Filed: Oct 10, 2024 · CIK: 1857044
Sentiment: neutral
Topics: ownership-change, sec-filing, biotech
Related Tickers: INDP
TL;DR
**Meckler files 13D on Indaptus Therapeutics, watch for ownership changes.**
AI Summary
Jeffrey A. Meckler, filing on behalf of Indaptus Therapeutics, Inc., has submitted a Schedule 13D filing on October 10, 2024. This filing relates to the common stock of Indaptus Therapeutics, Inc. The filing indicates a change in beneficial ownership or a new filing requirement as of August 4, 2023. Meckler's address is listed as c/o Indaptus Therapeutics, Inc. in New York.
Why It Matters
This filing signals a potential shift in control or significant stakeholding in Indaptus Therapeutics, Inc., which could impact the company's strategic direction and stock performance.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant changes in beneficial ownership, which can lead to increased volatility and potential strategic shifts for the company.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Subject Company
- Jeffrey A. Meckler (person) — Filing Person
- 0001857044 (company) — Central Index Key for Indaptus Therapeutics, Inc.
- 0001506916 (person) — Central Index Key for Jeffrey A. Meckler
- 45339J105 (dollar_amount) — CUSIP Number for Indaptus Therapeutics, Inc. Common Stock
- 3 Columbus Circle, 15th Floor, New York, NY 10019 (company) — Business and Mail Address for Indaptus Therapeutics, Inc.
- 740 Broadway, 9th Floor, New York, NY 10003 (company) — Mail Address for Jeffrey A. Meckler
FAQ
What is the primary purpose of this Schedule 13D filing for Indaptus Therapeutics, Inc.?
The filing is a Schedule 13D, indicating a change in beneficial ownership or a new filing requirement for Indaptus Therapeutics, Inc. as of August 4, 2023.
Who is the individual filing this Schedule 13D statement?
The filing person is Jeffrey A. Meckler.
What is the CUSIP number for the securities in question?
The CUSIP number for Indaptus Therapeutics, Inc. Common Stock is 45339J105.
What is the business address of Indaptus Therapeutics, Inc.?
The business address is 3 Columbus Circle, 15th Floor, New York, NY 10019.
What was the former name of Indaptus Therapeutics, Inc. and when did the name change occur?
The former name was Intec Parent Inc., and the date of the name change was April 14, 2021.
Filing Stats: 1,755 words · 7 min read · ~6 pages · Grade level 12.5 · Accepted 2024-10-10 16:10:11
Key Financial Figures
- $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class o
- $274,000 — ggregate consideration of approximately $274,000. In addition, on August 8, 2024, the Re
- $155,000.90 — suer for an aggregate purchase price of $155,000.90. The Reporting Person used personal fun
- $1.825 — o;Warrants”) for consideration of $1.825 for one Share and a Warrant to purchase
- $1.70 — The exercise price of the Warrants was $1.70 per share. The Warrants are immediately
Filing Documents
- formsc13d.htm (SC 13D) — 77KB
- 0001493152-24-040734.txt ( ) — 78KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : October 10, 2024 By: /s/ Jeffrey A. Meckler Name: Jeffrey A. Meckler